Centre de Documentation Campus Montignies
Horaires :
Lundi : 8h-18h30
Mardi : 8h-17h30
Mercredi 9h-16h30
Jeudi : 8h30-18h30
Vendredi : 8h30-12h30 et 13h-14h30
Votre centre de documentation sera exceptionnellement fermé de 12h30 à 13h ce lundi 18 novembre.
Egalement, il sera fermé de 12h30 à 13h30 ce mercredi 20 novembre.
Lundi : 8h-18h30
Mardi : 8h-17h30
Mercredi 9h-16h30
Jeudi : 8h30-18h30
Vendredi : 8h30-12h30 et 13h-14h30
Votre centre de documentation sera exceptionnellement fermé de 12h30 à 13h ce lundi 18 novembre.
Egalement, il sera fermé de 12h30 à 13h30 ce mercredi 20 novembre.
Bienvenue sur le catalogue du centre de documentation du campus de Montignies.
Détail de l'auteur
Auteur Anne-Christine Bay-Jensen |
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives / Yves Henrotin in Annals of physical and rehabilitation medicine, Vol. 59, n° 3 (June 2016)
[article]
Titre : Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives Type de document : texte imprimé Auteurs : Yves Henrotin, Auteur ; Christelle Sanchez, Auteur ; Anne-Christine Bay-Jensen, Auteur Année de publication : 2016 Article en page(s) : p. 145-148 Langues : Anglais (eng) Français (fre) Mots-clés : Arthrose Osteoarthritis,Biomarkers,Cartilage,Extracellular matrix Résumé : Specific soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on cartilage metabolism and provide crucial information about the mechanisms of drug action. In this review, we address key questions concerning the use of biomarkers in OA management: Why do we need soluble biomarkers? What are the most widely investigated biomarkers derived from cartilage extracellular matrix? What are the most common pitfalls in interpreting soluble biomarker measurements? What are the perspectives and future research directions in this field? We review current evidence to propose that cartilage-derived soluble biomarkers are complementary “drug development tools” that can be applied during drug development from preclinical research to clinical evaluation. In the future, such biomarkers could be surrogate markers of clinical and/or imaging outcomes. Successful standardization and implementation of automated biomarker assays will facilitate their use in companion diagnostics in the context of personalized medicine for enhanced management of OA. Permalink : ./index.php?lvl=notice_display&id=45214
in Annals of physical and rehabilitation medicine > Vol. 59, n° 3 (June 2016) . - p. 145-148[article] Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives [texte imprimé] / Yves Henrotin, Auteur ; Christelle Sanchez, Auteur ; Anne-Christine Bay-Jensen, Auteur . - 2016 . - p. 145-148.
Langues : Anglais (eng) Français (fre)
in Annals of physical and rehabilitation medicine > Vol. 59, n° 3 (June 2016) . - p. 145-148
Mots-clés : Arthrose Osteoarthritis,Biomarkers,Cartilage,Extracellular matrix Résumé : Specific soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on cartilage metabolism and provide crucial information about the mechanisms of drug action. In this review, we address key questions concerning the use of biomarkers in OA management: Why do we need soluble biomarkers? What are the most widely investigated biomarkers derived from cartilage extracellular matrix? What are the most common pitfalls in interpreting soluble biomarker measurements? What are the perspectives and future research directions in this field? We review current evidence to propose that cartilage-derived soluble biomarkers are complementary “drug development tools” that can be applied during drug development from preclinical research to clinical evaluation. In the future, such biomarkers could be surrogate markers of clinical and/or imaging outcomes. Successful standardization and implementation of automated biomarker assays will facilitate their use in companion diagnostics in the context of personalized medicine for enhanced management of OA. Permalink : ./index.php?lvl=notice_display&id=45214 Exemplaires (1)
Cote Support Localisation Section Disponibilité Revue Revue Centre de Documentation HELHa Campus Montignies Armoires à volets Document exclu du prêt - à consulter sur place
Exclu du prêt